Naperville, IL -- (SBWire) -- 07/08/2013 --Reportstack, provider of premium market research reports announces the addition of Virometix AG - Product Pipeline Review - 2013 market report to its offering
Virometix AG - Product Pipeline Review - 2013

Summary

Global Market Direct's pharmaceuticals report, Virometix AG - Product Pipeline Review - 2013 provides data on the Virometix AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Virometix AG's corporate website, SEC filings, investor presentations and featured press releases, both from Virometix AG and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Virometix AG - Brief Virometix AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Virometix AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Virometix AG with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Virometix AG's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Virometix AG's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Virometix AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Virometix AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Virometix AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Virometix AG and identify potential opportunities in those areas.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/116747/virometix-ag-product-pipeline-review-2013.html